Article
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Clinical pharmacology and therapeutics - 1 Nov 2011
Desta Z, Kreutz Y, Nguyen A T, Li L, Skaar T, Kamdem L K, Henry N L, Hayes D F, Storniolo A M, Stearns V, Hoffmann E, Tyndale R F, Flockhart D A
Abstract excerpt
The associations between plasma letrozole concentrations and CYP2A6 and CYP3A5 genetic variants were tested in the Exemestane and Letrozole Pharmacogenomics (ELPH) trial. ELPH is a multicenter, open-label prospective clinical trial in women randomly assigned (n≈250 in each arm) to receive 2 years of treatment with either oral letrozole (2.5 mg/day) or oral exemestane (25 mg/day). CYP2A6 and CYP3A showed effects...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.